|本期目录/Table of Contents|

[1]洪原城,林平冬,张江灵,等.晚期非小细胞肺癌骨转移的骨相关事件 及生存分析[J].医学研究与战创伤救治(原医学研究生学报),2009,11(02):124-126.
　HONG Yuan-cheng,LIN Ping-dong,ZHANG Jiang-ling,et al.Skeletal-related events of skeletal metastases in advanced stage non-small cell lung cancer and survival analysis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(02):124-126.
点击复制

晚期非小细胞肺癌骨转移的骨相关事件 及生存分析()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第11卷
期数:
2009年02期
页码:
124-126
栏目:
出版日期:
2009-03-20

文章信息/Info

Title:
Skeletal-related events of skeletal metastases in advanced stage non-small cell lung cancer and survival analysis
文章编号:
1672-271X(2009)02-0124-03
作者:
洪原城; 林平冬; 张江灵; 刘甲兴; 黄种杰
解放军第180医院心肾呼吸科，福建泉州 362000
Author(s):
HONG Yuan-cheng; LIN Ping-dong; ZHANG Jiang-ling; LIU Jia-xing; HUANG Zhong-jie
Department of Cardiology，the 180th Hospital of PLA，Quanzhou 362000，Fujian，China
关键词:
非小细胞肺癌; 骨转移; 骨相关事件; 生存分析
Keywords:
Non-small cell lung cancer; Skeletal-related event; Skeletal metastasis; Survival analysis
分类号:
R735.7
DOI:
-
文献标志码:
A
摘要:
目的 研究晚期非小细胞肺癌骨转移的骨相关事件(SRE)及其生存分析。方法 回顾性研究自2002年2月～2006年1月间我院治疗的230例晚期非小细胞肺癌患者，评价其TNM分期、骨转移的诊断(放射性核素扫描、X线片、MRI、CT及PET-CT检查)，比较肺癌不同分期骨相关事件的发生率及生存时间。结果 在230例晚期非小细胞肺癌患者中发现骨转移70例(30.4%)，其中SRE35例(15.2%)；Ⅲ期患者骨转移发生率14.7%(14/95)低于Ⅳ期41.5%(56/135)，有统计学意义(P<0.01)；但Ⅲ期患者骨转移合并SRE发生率与Ⅳ期相近，未见统计学意义(P>0.05)。无骨转移组患者平均存活时间高于有骨转移组，未合并SRE组患者存活时间长于合并SRE组，两组比较差异有统计学意义(P均<0.01)。结论 在晚期非小细胞肺癌的治疗期间，临床上应尽早阻止骨相关事件的发生。
Abstract:
Objective To investigate the clinical impact of skeletal-related events (SRE) in advanced stage non-small cell lung cancer (NSCLC) patients，and to compare differences in the therapeutic outcome between patients with and without skeletal metastases or SRE.Methods We retrospectively investigated the charts of all 230 patients with advanced stage NSCLC between February 2002 and January 2006. We assessed their TNM stage，presence of skeletal metastases (on bone scintigraphy，MRI，PET-CT and plain X-ray films)，and outcome parameters such as SRE and survival.Results A total of 70 patients (30.4%) were found to have skeletal metastases during their clinical course and 35 patients (50%) out of all 70 patients had SRE. Among 135 stage IV patients，a total of 56 (41%) had skeletal metastases，and 25 of these 56 patients (45%) had SRE. The most common SRE were the need for radiotherapy (34.3%) and hypercalcemia (20%). Patients with SRE tended to have worse survival，while no significant difference of survival was observed between patients with and without skeletal metastases.Conclusion It seems to be important to prevent SRE during the treatment of advanced stage NSCLC，so further studies evaluating bisphosphonates in combination with chemotherapy are warranted.

参考文献/References:

[1]Coleman RE. Skeletal complications of malignancy[J].Canc- er，1997，80(8 suppl):1588.
[2]Delea T，Langer C，McKiernan J，et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer[J].Oncology，2004,67:390-396.
[3]陈万青，张思维，李连弟，等.中国部分市县1998-2002年肺癌的发病与死亡[J].中国肿瘤,2006,15(9):570-574.
[4]Kosteva J， Langer CJ. Incidence and distribution of skeletal metastases in NSCLC in the era of PET[J]. Lung Cancer，2004，46:45.
[5]郭永庆，梁朝阳. 肺癌骨转移的治疗进展[J]. 北京医学，2007,29(1):50,53.
[6]Delea T，Langer C，McKiernan J，et al.The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer[J].Oncology，2004, 67:390-396.
[7]Rosen LS，Gordon D，Kaminski M，et al.Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma；a randomized，double blind，multicenter，comparative trial[J]. Cancer，2003，98:735-744.
[8]Saad F，Gleason DM，Murray R.Zoledronic acid is well toler- ated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone[J].J Urol，2003，169:394.
[9]Rosen LS，Gordon D，Tchekmedyian NS,et al.Long-term eff- icacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors; a randomized phase III, double-blind, placebo-controlled trial[J].Cancer，2004，100:2613-2621.

相似文献/References:

[1]周诚忠,夏炎春,夏海波.三维适形放射治疗老年非小细胞肺癌60例[J].医学研究与战创伤救治(原医学研究生学报),2009,11(01):20.
　ZHOU Cheng-zhong,XIA Yan-chun,XIA Hai-bao.Analysis of curative effect on 60 elderly non-small cell lung cancer patients treated by three-dimensional conformal radiotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(02):20.
[2]陈芳芳 综述,李晓军 审校.细胞凋亡在介导非小细胞肺癌耐药调节中的作用[J].医学研究与战创伤救治(原医学研究生学报),2015,17(03):286.[doi:10.3969/j.issn.1672-271X.2015.03.020]
[3]周向毅,丁妍,陈邦元,等.复方康复灵对体部伽玛刀治疗非小细胞肺癌引起的急性放射反应的防护作用[J].医学研究与战创伤救治(原医学研究生学报),2015,17(05):455.[doi:10.3969/j.issn.1672-271X.2015.05.002]
　ZHOU Xiang-yi,DING Yan,CHEN Bang-yuan,et al.Protective effect of compound Kangfuling on body gamma knife in treating acute radiation reaction of non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(02):455.[doi:10.3969/j.issn.1672-271X.2015.05.002]
[4]周小林.CRP和Alb与初诊断的非小细胞肺癌临床病理特征联系及预后价值分析[J].医学研究与战创伤救治(原医学研究生学报),2016,18(05):489.[doi:10.3969/j.issn.1672-271X.2016.05.012]
　ZHOU Xiao-lin.Prognostic evaluation of CRP and Alb in newly diagnosed non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(02):489.[doi:10.3969/j.issn.1672-271X.2016.05.012]
[5]徐瑞彤,孙康俊,戴冠群,等.抗雌激素治疗对耐酪氨酸激酶抑制剂非小细胞肺癌细胞株抗增殖作用的机制探讨[J].医学研究与战创伤救治(原医学研究生学报),2017,19(06):581.[doi:10.3969/j.issn.1672-271X.2017.06.006]
　XU Rui-tong,SUN Kang-jun,DAI Guan-qun,et al.The antitumor effect of anti-estrogen therapy on non-small cell lung cancer cell lines with acquired resistance to EGFR-TKI[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(02):581.[doi:10.3969/j.issn.1672-271X.2017.06.006]
[6]张驰,张久荣,童维佳,等.芪胶升白胶囊对改善非小细胞肺癌患者化疗所致中性粒细胞减少症的临床药物疗效研究与分析[J].医学研究与战创伤救治(原医学研究生学报),2018,20(01):26.[doi:10.3969/j.issn.1672-271X.2018.01.006]
　ZHANG Chi,ZHANG Jiu-rong,TONG Wei-jia,et al.Study and analysis on clinical drug efficacy of Qijiaoshengbai capsule on the treatment of non-small cell lung cancer patients with neutropenia caused by chemotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(02):26.[doi:10.3969/j.issn.1672-271X.2018.01.006]
[7]沈凯凯综述,吕镗烽审校.外泌体在非小细胞肺癌中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2018,20(04):399.[doi:10.3969/j.issn.1672-271X.2018.04.016]
[8]王毅,权琳.培美曲塞与顺铂联合吉非替尼治疗对非小细胞肺癌患者T细胞亚群及细胞因子的影响[J].医学研究与战创伤救治(原医学研究生学报),2020,22(01):43.[doi:10.3969/j.issn.1672-271X.2020.01.010]
　WANGYi,QUANLin.Effects of pemetrexed and cisplatin combined with gefitinib on T cell subsets and cytokines in patients with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(02):43.[doi:10.3969/j.issn.1672-271X.2020.01.010]
[9]蔡猛,周光新.非小细胞肺癌骨转移的治疗研究进展[J].医学研究与战创伤救治(原医学研究生学报),2022,24(4):408.[doi:10.3969/j.issn.1672-271X.2022.04.015]
　CAI Meng,ZHOU Guang-xin.Research progress in the treatment of bone metastasis in non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(02):408.[doi:10.3969/j.issn.1672-271X.2022.04.015]
[10]顾晓凌,吴冠楠,王栋,等.免疫检查点抑制剂相关甲状腺不良事件对PD-1单抗治疗非小细胞肺癌的预测价值[J].医学研究与战创伤救治(原医学研究生学报),2023,25(1):7.[doi:10.3969/j.issn.1672-271X.2023.01.002]
　GU Xiaoling,WU Guannan,WANG Dong,et al.Immune-related thyroid function abnormality is a prognostic factor for non-small cell lung cancer patients treated with PD-1 monoclonal antibody[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(02):7.[doi:10.3969/j.issn.1672-271X.2023.01.002]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2013-11-20